Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
111: One cycle of adjuvant BEP in high-risk stage 1 NSGCTT
NCT01726374Phase 3Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Feb 2010
- Primary completion
- Aug 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bleomycin, etoposide, Cisplatin micelle injection (HA132) in testicular non-seminomatous germ cell tumor (NSGCT), sponsored by The Institute of Cancer Research. Started Feb 2010; status: completed.
02
Drugs
bleomycinetoposideCisplatin micelle injection (HA132)
03
Conditions
testicular non-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on NCT01726374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01726374.